期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

甲状腺髓样癌的靶向治疗 被引量：7

Targeted Therapies for Medullary Thyroid Cancer
原文传递
导出
摘要 甲状腺癌是内分泌系统最常见的恶性肿瘤,也是近年来发病率上升最快的恶性肿瘤[1]。其病理类型主要包括分化型甲状腺癌（甲状腺乳头状癌和甲状腺滤泡状癌）、甲状腺髓样癌（medullary thyroid cancer,MTC）和未分化癌。其中,MTC为低分化癌,属于中度恶性的肿瘤。临床上MTC具有早期侵犯区域淋巴结和易向肝、肺、骨等远处转移的倾向。
作者 徐德全 代文杰
机构地区 哈尔滨医科大学附属第一医院甲状腺乳腺细胞移植外科
出处 《中国普外基础与临床杂志》 CAS 2014年第12期1579-1582,共4页 Chinese Journal of Bases and Clinics In General Surgery
关键词 甲状腺髓样癌 靶向治疗
分类号 R736.1 [医药卫生—肿瘤]
  • 相关文献

参考文献27

  • 1Wartofsky L. Increasing world incidence of thyroid cancer: incre- ased detection or higher radiation exposure ? [J]. Hormones (Athens), 2010, 9(2): 103-108.
  • 2Kazaure HS, Roman SA, Sosa JA. Medullary thyroid microcar- cinoma: a population-level analysis of 310 patients [ J ]. Cancer, 2012, 118(3): 620-627.
  • 3Sippel RS, Kunnimalaiyaan M, Chen H. Current management of medullary thyroid cancer [J]. Oncologist, 2008, 13(5): 539-547.
  • 4Schulten H J, AI-Maghrabi J, A1-Ghamdi K, et al. Mutational screening ofRET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNBI in medullary thyroid carcinoma [J]. Anticancer Res, 2011, 31(12): 4179-4183.
  • 5de Groot JW, Links TP, Plukker JT, et al. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors[J]. Endocr Rev, 2006, 27(5): 535-560.
  • 6马维昌,代文杰.遗传性甲状腺髓样癌的诊断及外科处理[J].外科理论与实践,2013,18(6):586-589. 被引量：2
  • 7陈曦,李宏为.遗传性甲状腺癌[J].中国实用外科杂志,2010,30(10):828-830. 被引量：7
  • 8Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study [J]. J Clin Endocrinol Metab, 2008, 93(3): 682-687.
  • 9Segouffin-Cariou C, Billaud M. Transforming ability of MEN2A- RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway [J]. J Biol Chem, 2000, 275(5): 3568-3576.
  • 10Sherman SI. Advances in chemotherapy of differentiated epithe- lial and medullary thyroid cancers [J]. J Clin Endocrinol Metab, 2009, 94(5): 1493-1499.

二级参考文献36

  • 1Malchoff CD, Malchoff DM. Familial nonmedullary thyroid carcinoma[J]. Cancer Control, 2006, 13(2): 106-110.
  • 2Vriens MR,Sub I,Moses W, et al. Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer [J]. Thyroid, 2009, 19(12): 1343-1349.
  • 3Morrison PJ, Atkinson AB. Genetic aspects of familial thyroid cancer [J ]. Oncologist ,2009,14 ( 6 ): 571-577.
  • 4Jazdzewski K, Liyanarachchi S, Swiemiak M, et al. Polymorphic mature microRNAs from passenger strand of pre-miR-146acontribute to thyroid cancer[J]. Proc Natl Acad Sci USA ,2009, 107 (35):1502-1505.
  • 5Sippel RS, Caron NR, Clark OH. An evidence-based approach to familial non-medullary thyroid cancer: screening, clinical management, and follow-up [J]. World J Surg, 2007, 31 (5): 924--933.
  • 6Machens A, Dralle H. Multiple endocrine neoplasia type 2 and the RET protooncogene: from bedside to bench to bedside [J]. Mol Cell Endocrinol,2006, 247 ( 1-2 ): 34-40.
  • 7Sakorafas GH, Friessl H, Peros G. The genetic basis of hereditary medullary thyraid cancer: clinical implications for the surgeon, with a particular emphasis on the role of prophylactic thyroidectomy [J]. Endocrine-Related Cancer, 2008, 15 (4): 871-884.
  • 8Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the american thyroid association[J]. Thyroid, 2009, 19(6): 565-612.
  • 9de Groot JW, Links TP, Plukker JT, et al. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors[J ]. Endocr Rev, 2006, 27(5 ):535-560.
  • 10Albuquerque RJ,Hayashi T,Cho WG,et al.Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth[J].Nat Med,2009,15(9):1023-1030.

共引文献17

同被引文献72

  • 1Yip L. Molecular markers for thyroid cancer diagnosis, prognosis, and targeted therapy[ J]. J Surg Oncol, 2015, 111 (1) :43-50.
  • 2Gild ML, Bullock M, Robinson BG, et al. Muhikinase inhibitors: a new option for the treatment of thyroid cancer [ J ]. Nat Rev Endocrinol, 2011, 7(10) :617-624.
  • 3Carhill AA, Cabanilas ME, Jimenez C, et al. The noninvestigalinnal use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring [ J ]. J Clin Endocrinol Metab, 2013, 98(1):31-42.
  • 4Brose MS,Nutting CM,Jarzab B,et al. Sorafenib in radinactive iedine- refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial [ J ]. Lancet, 2014, 384(9940) :319-328.
  • 5Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in paliems with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase Ⅲ trial[J]. J Clin Oncol, 2012, 30(2) :134-141.
  • 6Elisei R, Schlumberger MJ, Mailer SP, et al. Cabozantinib in progressive medullary thyroid cancer[J]. J Clin Oncol, 2013, 31 ( 29 ) : 3639-3646.
  • 7O'Neill JP, Shaha AR. Anaplastic thyroid cancer[ J]. Oral Oncol, 2013, 49(7) :702-706.
  • 8Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognosec factors, and treatment approaches[ J ]. Ann Surg Oncol, 2006, 13(4) :453-464.
  • 9Sosa JA, Elisei R, Jarzab B, et al. Randomized safety and efficacy study of fosbretabulin with paelitaxel/earboplatin against anaplastie thyroid carcinoma[J]. Thyroid, 2014, 24(2):232-240.
  • 10World Cancer Report. Version 2014. http://www.iarc.fr/en/publications/books/wcr/wcr-order. php.

引证文献7

二级引证文献24

中国普外基础与临床杂志
2014年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部